Found: 41
Select item for more details and to access through your institution.
Adipokines and Insulin Resistance.
- Published in:
- Molecular Medicine, 2008, v. 14, n. 11/12, p. 741, doi. 10.2119/2008-00058.Rabe
- By:
- Publication type:
- Article
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1151, doi. 10.1111/dom.14017
- By:
- Publication type:
- Article
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 2, p. 266, doi. 10.1111/dom.12814
- By:
- Publication type:
- Article
Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2013, v. 51, n. 2, p. 132, doi. 10.5414/CP201794
- By:
- Publication type:
- Article
Expression of Human Chemerin Induces Insulin Resistance in the Skeletal Muscle but Does Not Affect Weight, Lipid Levels, and Atherosclerosis in LDL Receptor Knockout Mice on High-Fat Diet.
- Published in:
- Diabetes, 2010, v. 59, n. 11, p. 2898, doi. 10.2337/db10-0362
- By:
- Publication type:
- Article
Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques.
- Published in:
- PLoS ONE, 2009, v. 4, n. 3, p. 1, doi. 10.1371/journal.pone.0004733
- By:
- Publication type:
- Article
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes.
- Published in:
- Kidney International, 2014, v. 86, n. 5, p. 1057, doi. 10.1038/ki.2014.246
- By:
- Publication type:
- Article
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
- Published in:
- Journal of Clinical Investigation, 2014, v. 124, n. 2, p. 499, doi. 10.1172/JCI72227
- By:
- Publication type:
- Article
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
- Published in:
- Diabetes & Vascular Disease Research, 2016, v. 13, n. 2, p. 119, doi. 10.1177/1479164115616901
- By:
- Publication type:
- Article
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials.
- Published in:
- Diabetes & Vascular Disease Research, 2015, v. 12, n. 2, p. 90, doi. 10.1177/1479164114559852
- By:
- Publication type:
- Article
Structural basis of endothelial lipase tropism for HDL.
- Published in:
- FASEB Journal, 2004, v. 18, n. 15, p. 1891, doi. 10.1096/fj.03-1307fje
- By:
- Publication type:
- Article
Genetic variants of adiponectin receptor 2 are associated with increased adiponectin levels and decreased triglyceride/VLDL levels in patients with metabolic syndrome.
- Published in:
- Cardiovascular Diabetology, 2006, v. 5, p. 11, doi. 10.1186/1475-2840-5-11
- By:
- Publication type:
- Article
The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1.
- Published in:
- Journal of Clinical Apheresis, 2002, v. 17, n. 1, p. 38, doi. 10.1002/jca.10010
- By:
- Publication type:
- Article
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
- Published in:
- European Heart Journal, 2016, v. 37, n. 19, p. 1526, doi. 10.1093/eurheartj/ehv728
- By:
- Publication type:
- Article
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
- Published in:
- Cardiovascular Diabetology, 2018, v. 17, p. 1, doi. 10.1186/s12933-018-0682-3
- By:
- Publication type:
- Article
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
- Published in:
- Cardiovascular Diabetology, 2015, v. 14, n. 1, p. 1, doi. 10.1186/s12933-015-0314-0
- By:
- Publication type:
- Article
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
- Published in:
- Cardiovascular Diabetology, 2015, v. 14, n. 1, p. 1, doi. 10.1186/s12933-014-0169-9
- By:
- Publication type:
- Article
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4- week study.
- Published in:
- Cardiovascular Diabetology, 2015, v. 14, n. 1, p. 85, doi. 10.1186/s12933-014-0169-9
- By:
- Publication type:
- Article
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME).
- Published in:
- Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 1, doi. 10.1186/1475-2840-13-102
- By:
- Publication type:
- Article
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
- Published in:
- Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 2, doi. 10.1186/1475-2840-13-28
- By:
- Publication type:
- Article
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
- Published in:
- Cardiovascular Diabetology, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1475-2840-12-129
- By:
- Publication type:
- Article
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
- Published in:
- Cardiovascular Diabetology, 2013, v. 12, n. 1, p. 1, doi. 10.1186/1475-2840-12-70
- By:
- Publication type:
- Article
Long-term LDL apheresis does not stably improve hemorheology in hypercholesterolemic patients with coronary artery disease.
- Published in:
- Clinical Hemorheology & Microcirculation, 2009, v. 41, n. 2, p. 137, doi. 10.3233/CH-2009-1166
- By:
- Publication type:
- Article
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141085
- By:
- Publication type:
- Article
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
- Published in:
- 2017
- By:
- Publication type:
- journal article
Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Erratum.
- Published in:
- 2015
- By:
- Publication type:
- Correction Notice
Erratum.
- Published in:
- 2015
- By:
- Publication type:
- Correction Notice
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2015, v. 38, n. 3, p. 394, doi. 10.2337/dc14-2365
- By:
- Publication type:
- Article
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin.
- Published in:
- Diabetes Care, 2015, v. 38, n. 3, p. 384, doi. 10.2337/dc14-2364
- By:
- Publication type:
- Article
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension.
- Published in:
- Diabetes Care, 2015, v. 38, n. 3, p. 420, doi. 10.2337/dc14-1096
- By:
- Publication type:
- Article
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes.
- Published in:
- Diabetes Care, 2014, v. 37, n. 7, p. 1815, doi. 10.2337/dc13-3055
- By:
- Publication type:
- Article
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
- Published in:
- Diabetes Care, 2014, v. 37, n. 6, p. 1650, doi. 10.2337/dc13-2105
- By:
- Publication type:
- Article
Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial.
- Published in:
- Diabetes Care, 2014, v. 37, n. 5, p. 1480, doi. 10.2337/dc13-2338
- By:
- Publication type:
- Article
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin.
- Published in:
- Diabetes Care, 2013, v. 36, n. 12, p. 4015, doi. 10.2337/dc13-0663
- By:
- Publication type:
- Article
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 11, p. 3396, doi. 10.2337/dc12-2673
- By:
- Publication type:
- Article